https://scholars.lib.ntu.edu.tw/handle/123456789/630364
標題: | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial | 作者: | Herbst, Roy S Wu, Yi-Long John, Thomas Grohe, Christian Majem, Margarita Wang, Jie Kato, Terufumi Goldman, Jonathan W Laktionov, Konstantin Kim, Sang-We CHONG-JEN YU Vu, Huu Vinh Lu, Shun Lee, Kye Young Mukhametshina, Guzel Akewanlop, Charuwan de Marinis, Filippo Bonanno, Laura Domine, Manuel Shepherd, Frances A Urban, Damien Huang, Xiangning Bolanos, Ana Stachowiak, Marta Tsuboi, Masahiro |
公開日期: | 1-四月-2023 | 卷: | 41 | 期: | 10 | 來源出版物: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 摘要: | The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630364 | ISSN: | 0732-183X 1527-7755 |
DOI: | 10.1200/JCO.22.02186 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。